^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ZFN modified T cell (SB-313)

    i
    Associations
    News

    Trials

    Company:
    Sangamo Therap
    Drug class:
    Immunomodulator, Cytotoxic T lymphocyte stimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 (NCT01082926)
    Phase 1
    City of Hope Medical Center
    Completed
    Last update posted :
    06/08/2015
    Initiation :
    05/01/2010
    Primary completion :
    09/01/2013
    Completion :
    09/01/2013
    IL2
    |
    CD123 expression
    |
    Proleukin (aldesleukin) • ZFN modified T cell (SB-313)